ECSP21044662A - Gen suicida - Google Patents

Gen suicida

Info

Publication number
ECSP21044662A
ECSP21044662A ECSENADI202144662A ECDI202144662A ECSP21044662A EC SP21044662 A ECSP21044662 A EC SP21044662A EC SENADI202144662 A ECSENADI202144662 A EC SENADI202144662A EC DI202144662 A ECDI202144662 A EC DI202144662A EC SP21044662 A ECSP21044662 A EC SP21044662A
Authority
EC
Ecuador
Prior art keywords
tnf
alpha
cells
mutants
individual
Prior art date
Application number
ECSENADI202144662A
Other languages
English (en)
Spanish (es)
Inventor
Elizabeth Shpall
Katy Rezvani
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68848450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21044662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of ECSP21044662A publication Critical patent/ECSP21044662A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/25—Suicide switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ECSENADI202144662A 2018-11-19 2021-06-18 Gen suicida ECSP21044662A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769405P 2018-11-19 2018-11-19
US201862773372P 2018-11-30 2018-11-30
US201962791464P 2019-01-11 2019-01-11

Publications (1)

Publication Number Publication Date
ECSP21044662A true ECSP21044662A (es) 2021-09-30

Family

ID=68848450

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202144662A ECSP21044662A (es) 2018-11-19 2021-06-18 Gen suicida

Country Status (18)

Country Link
US (1) US20220023343A1 (cg-RX-API-DMAC7.html)
EP (1) EP3883959A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022513099A (cg-RX-API-DMAC7.html)
KR (1) KR20210093977A (cg-RX-API-DMAC7.html)
CN (1) CN113272320A (cg-RX-API-DMAC7.html)
AU (1) AU2019384115A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009634A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120349A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001300A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007824A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP21044662A (cg-RX-API-DMAC7.html)
IL (1) IL283242A (cg-RX-API-DMAC7.html)
MX (1) MX2021005847A (cg-RX-API-DMAC7.html)
PE (1) PE20211236A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551142A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105238YA (cg-RX-API-DMAC7.html)
TW (1) TW202039538A (cg-RX-API-DMAC7.html)
WO (1) WO2020106619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773789B2 (ja) 2020-03-28 2025-11-20 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 癌の治療のための細胞免疫療法
AU2022372894A1 (en) 2021-10-20 2024-04-18 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023177954A1 (en) * 2022-03-18 2023-09-21 University Of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
US6143866A (en) 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
AU2011258425B2 (en) * 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
CA2962251A1 (en) * 2014-10-03 2016-04-07 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
MX2018001568A (es) * 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
CN107337737B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用
CN107312098B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CN107312097B (zh) * 2017-07-18 2020-06-16 深圳市免疫基因治疗研究院 一种基于cd30的嵌合抗原受体及其应用
CN107245106B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107245107B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
WO2020106619A1 (en) 2020-05-28
EP3883959A1 (en) 2021-09-29
CN113272320A (zh) 2021-08-17
CA3120349A1 (en) 2020-05-28
JP2022513099A (ja) 2022-02-07
IL283242A (en) 2021-07-29
CL2021001300A1 (es) 2022-03-18
BR112021009634A2 (pt) 2021-08-10
PE20211236A1 (es) 2021-07-09
TW202039538A (zh) 2020-11-01
PH12021551142A1 (en) 2021-10-25
CO2021007824A2 (es) 2021-06-30
KR20210093977A (ko) 2021-07-28
MX2021005847A (es) 2021-09-23
AU2019384115A1 (en) 2021-06-17
SG11202105238YA (en) 2021-06-29
US20220023343A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
CO2021007824A2 (es) Gen suicida
MX2021008143A (es) Metodos para cosechar cultivos de celulas de mamifero.
CO2021006365A2 (es) Composiciones y métodos para expresar el factor ix
WO2018201056A8 (en) Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
BRPI0812091A2 (pt) Método para fabricar uma proteína policlonal recombinante
DK3737765T3 (da) Forstærkede immunceller med dobbelt shrna og sammensætning dermed
MX2019012017A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
EP4188442A4 (en) COMPOSITIONS CONTAINING EX-VIVO-DEPLEATED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EP4286511A3 (en) Method to treat cancer with engineered t-cells
MY172618A (en) Mice that make binding proteins comprising vl domains
EP3874023A4 (en) ENHANCED PERFUSION CELL CULTURE PROCEDURE WITH CONTINUOUS HARVESTING AND WITHOUT CELL BLEEDING
MX2012011636A (es) Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en eltratamiento de enfermedades asociadas a una proliferacion celulara no deseada.
BR112021019365A2 (pt) Métodos para identificar um indivíduo que tem câncer, para selecionar uma terapia, para identificar uma interação proteína-proteína e para identificar um modulador, métodos de tratamento de um indivíduo com câncer, de identificação, de seleção de uma terapia e de identificação de um modulador, coleções de polipeptídeos, de vetores e de células e moduladores isolados
BR112022003852A2 (pt) Métodos de preparação de células t para terapia de células t
MX2017005925A (es) Metodos de producción de proteínas de cadena doble en bacterias.
BR112016027797A2 (pt) métodos e meios de cultura de células compreendendo n-acetilcisteína
BR112018070293A2 (pt) diferenciação de células-tronco pluripotentes em células do endoderma intestinal do intestino médio
MX2016014718A (es) Cocultivo de propionibacteria y levadura.
EP4069831A4 (en) Genetically engineered double negative t cells as an adoptive cellular therapy
EA201992828A1 (ru) Способы культивирования клеток
CL2018000076A1 (es) Mejora del metabolismo de las microalgas de xilosa.